CNA FINANCIAL CORP
In the published model solve dated 2026-Q2, anchored at $49.31, CNA FINANCIAL CORP (CNA) is priced for 9.5% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• The controlling shareholder is the structural fact a buyer inherits: the FY2025 10-K discloses that ⟦"Loews beneficially owned approximately 92% of our outstanding shares of common stock as of December 31, 2025"⟧, so the tradable float is thin and no outside party can force a sale of the company. • Underwriting turned unprofitable in the first quarter of 2026, with the property and casualty combined ratio at 102.2 percent against 98.4 percent a year earlier, and 4.1 points of that came from cl
Is CNA overvalued? See what's priced in →
284 institutional managers reported holding CNA in 13F filings for the quarter ended 2026-03-31. 41 opened new positions that quarter. Held by AQR Capital, BlackRock, Two Sigma, among others. On the short side, 3.1M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (6.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CNA's share count is about flat over the past five years ($153.00M of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (15 and counting), raised 2 years straight; the current rate is $3.84 a share annually. Cash returned over the past three years: $2.98B in dividends and $90.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CNA over the trailing three years: 2023: 1 buy totaling $175.08M; 2025: 2 buys totaling $186k. 11 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CNA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-01 | -1.1% | -3.0% |
| 2023-10-31 | +2.2% | +5.8% |
| 2024-02-07 | +6.4% | -5.3% |
| 2024-05-07 | -0.5% | +3.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CNA's latest 8-K filings: 2026-08-03 (items 2.02, 9.01); 2026-05-04 (items 2.02, 9.01); 2026-04-29 (items 5.07); 2026-02-09 (items 2.02, 9.01); 2025-11-03 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.